Previously vaccinated children from 12 months of age, adolescents and adults NimenrixTM may be given as a booster dose to individuals who have previously received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see section 5.1).

NIMENRIX® (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Monograph Page 5 of 39 Protection Against Meningococcal Disease NIMENRIX will only confer protection against Neisseria meningitidis serogroups A, C, W-135 and Y. The vaccine will not protect against other Neisseria meningitidis serogroups.

Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis

Apr 4, 2014 · Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidisgroups A, C, W-135, and Y. 4.2 Posology and method of administration

NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Information. Product Monograph (download PDF, 429KB) Patient Information (download PDF, 94KB) Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means.

Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. From 1 July 2024, Nimenrix will be funded for eligible tamariki under 12 months of age as part of the special group programme.

Dec 18, 2024 · Nimenrix powder and solvent for solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Pfizer Limited

Oct 1, 2024 · NIMENRIX is a vaccine used to help prevent meningococcal disease, caused by four types of Neisseria meningitidis bacteria (types A, C, W and Y). NIMENRIX works by causing your body to produce its own protection (or antibodies), against these types of meningococcal bacteria. NIMENRIX cannot cause meningococcal disease.